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Abstract
Mitochondrial disorders have the highest incidence among congenital metabolic disorders
characterized by biochemical respiratory chain complex deficiencies. It occurs at a rate of 1
in 5,000 births, and has phenotypic and genetic heterogeneity. Mutations in about 1,500
nuclear encoded mitochondrial proteins may cause mitochondrial dysfunction of energy
production and mitochondrial disorders. More than 250 genes that cause mitochondrial dis-
orders have been reported to date. However exact genetic diagnosis for patients still
remained largely unknown. To reveal this heterogeneity, we performed comprehensive
genomic analyses for 142 patients with childhood-onset mitochondrial respiratory chain
complex deficiencies. The approach includes whole mtDNA and exome analyses using
high-throughput sequencing, and chromosomal aberration analyses using high-density oli-
gonucleotide arrays. We identified 37 novel mutations in known mitochondrial disease
genes and 3 mitochondria-related genes (MRPS23,QRSL1, and PNPLA4) as novel
PLOS Genetics | DOI:10.1371/journal.pgen.1005679 January 7, 2016 1 / 31
OPEN ACCESS
Citation: Kohda M, Tokuzawa Y, Kishita Y, Nyuzuki
H, Moriyama Y, Mizuno Y, et al. (2016) A
Comprehensive Genomic Analysis Reveals the
Genetic Landscape of Mitochondrial Respiratory
Chain Complex Deficiencies. PLoS Genet 12(1):
e1005679. doi:10.1371/journal.pgen.1005679
Editor: Gregory S. Barsh, Stanford University School
of Medicine, UNITED STATES
Received: August 7, 2015
Accepted: October 27, 2015
Published: January 7, 2016
Copyright: © 2016 Kohda et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by a grant of the
Innovative Cell Biology by Innovative Technology
(Cell Innovation Program) from the Ministry of
Education, Culture, Sports, Science and Technology
(MEXT), Japan to YO (http://cell-innovation.nig.ac.jp/
mext-life/english/index.html); the Support Project and
a grant of Strategic Research Center in Private
Universities from the MEXT, Japan to Saitama
Medical University Research Center for Genomic
Medicine (http://www.mext.go.jp/a_menu/koutou/
causative genes. We also identified 2 genes known to cause monogenic diseases (MECP2
and TNNI3) and 3 chromosomal aberrations (6q24.3-q25.1, 17p12, and 22q11.21) as
causes in this cohort. Our approaches enhance the ability to identify pathogenic gene muta-
tions in patients with biochemically defined mitochondrial respiratory chain complex defi-
ciencies in clinical settings. They also underscore clinical and genetic heterogeneity and
will improve patient care of this complex disorder.
Author Summary
Mitochondria play a crucial role in ATP biosynthesis and comprise proteins encoded in
both the nuclear and mitochondrial genomes. Although more than 250 mitochondrial dis-
ease-causing genes have been reported, the exact genetic causes in patients remain largely
unknown. Here, we aimed to provide further insights into the pathogenic mechanisms of
mitochondrial disorders. We investigated the genes encoded in the nuclear and mitochon-
drial genomes using comprehensive genomic analysis in 142 patients with mitochondrial
respiratory chain complex deficiencies. We identified 3 novel disease-causing mitochon-
dria-related genes (MRPS23, QRSL1, and PNPLA4) as well as other disease-causing genes
and novel pathogenic mutations in known mitochondrial disease-causing genes. All path-
ogenic mutations in this study are validated by genetic and/or functional evidence. Our
findings, including the achievement of firm genetic diagnoses for 49 of 142 patients
(34.5%), were higher than the general diagnosis rate of approximately 25% and demon-
strated the value of comprehensive genomic analysis. Accordingly, we have shed light on
the genetic heterogeneity underlying mitochondrial disorders.
Introduction
Human oxidative phosphorylation (OXPHOS) disease has the highest incidence among con-
genital metabolic disorders characterized by a biochemical respiratory chain complex deficien-
cies and is thought to occur at a rate of 1 in 5,000 births[1]. No more than 15–30% of pediatric
diseases diagnosed as mitochondrial disorders show mitochondrial DNA (mtDNA) abnormal-
ities[2,3]; the remaining cases occur because of defects in genes encoded in the nucleus. A cer-
tain amount of nuclear-encoded gene products are present in the mitochondria, and roughly
1,500 are thought to play important roles in mitochondrial function[4,5].
It is particularly difficult to diagnose patients with OXPHOS disease at the molecular level
because of the massive numbers of potentially involved nuclear genes and genes not yet linked
to human disease. Therefore, identification of the causative genes and an understanding of the
pathogenic mechanisms of OXPHOS disease remain unsolved challenges.
Recent studies[6,7] have shown that heterogeneous genetic backgrounds as well as genes
previously not linked to mitochondrial functions or localization are associated with this dis-
ease. However, because of phenotypic and locus heterogeneity, only a fraction of patients has
been identified to date. Limitations in target resequencing have motivated us to apply a com-
prehensive genomic analysis for more accurate molecular diagnosis and for the identification
of novel causative genes.
Here, we aimed to determine whether a comprehensive genomic analysis approach could be
used to reveal the broad spectrum of genetic background of the disease[8]. One hundred and
forty-two unrelated individuals with displayed childhood-onset mitochondrial respiratory
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chain complex deficiencies were selected. We applied long-range polymerase chain reaction
(PCR)-based whole mtDNA sequencing, whole exome sequencing (WES), and high-density
oligonucleotide arrays to identify single-nucleotide variants (SNVs), small insertions or dele-
tions (indels), and chromosomal aberrations for comprehensive genomic analyses.
Results
Comprehensive genomic analysis in 142 patients
In this study, 142 patients with childhood-onset mitochondrial respiratory chain complex defi-
ciencies were enrolled and subjected to comprehensive genomic analyses (detailed clinical
characteristics are described in S1 Table). A schematic workflow of these analyses is shown in
Fig 1. Comprehensive genomic analyses included three approaches: (i) amplicon-based whole
mtDNA sequencing for pathogenic mutations and large duplications/deletions, (ii) WES for
pathogenic mutations in nuclear DNA, and (iii) high-density oligonucleotide arrays for chro-
mosomal aberrations. The prioritized variants derived from each approach are described
below.
Prioritized variants in 142 patients
After comprehensive genomic analysis shown in Fig 1, rare variants were filtered out and prior-
itized on the basis of the strategy described below. For mtDNA variants, we targeted variants
confirmed and reported in MITOMAP[9]. Exome sequencing covered 89% (ranged: from
Fig 1. Schematic of comprehensive genomic analysis of 142 patients. All 142 patients were subjected to
mtDNA amplicon-based sequencing, WES, and high-density oligonucleotide array analysis in parallel.
Variants were filtered on the basis of their rarity in public databases and population-matched datasets. For
each analysis, candidate variants were prioritized on the basis of the type of variant. Candidate variants were
validated by Sanger sequencing and tested for segregation within the family if DNA was available. mtDNA,
mitochondrial DNA; pVUS, prioritized variant of unknown significance; CNV, copy number variation
doi:10.1371/journal.pgen.1005679.g001
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70%–to 98%) of the targeted bases, with more than 20-fold coverage. Detailed sequence statis-
tics is shown in S2 Table.
The precise strategy for WES variant prioritization is shown in S2 Fig. We evaluated our pri-
oritization pipeline to validate whether it could feasibly enrich known OXPHOS disease-caus-
ing genes or mitochondria-related genes (S3 Fig). Known OXPHOS disease-causing genes
were clearly enriched in disease cases, whereas no prioritized genes were detected in healthy
controls. Compared with healthy controls, mitochondria-related genes also exhibited a
1.64-fold enrichment. No enrichment was observed in randomly selected genes. These results
suggest that mitochondria-related gene enrichment is caused by unidentified causative genes.
To analyze chromosomal aberrations, we focused on rather large (>100 Kb) deletions or
duplications. For prioritizing candidate aberrations, we filtered out deleted or duplicated
regions found in the 524 in-house controls and manually curated the pathogenicity of the aber-
rations by referring to the OMIM, DGV, and DECIPHER databases.
A breakdown of the 142 patients according to prioritized variants is shown in Fig 2. Of the
142 patients with mitochondrial respiratory chain complex deficiencies, 102 (71.8%) harbored
at least 1 prioritized mtDNAmutation, nuclear gene mutation, or chromosomal abnormality.
Ten (7.0%) patients harbored mtDNAmutations, including one large deletion (S4 Fig). In 29
patients (20.4%), firm molecular diagnoses were made in 20 genes previously linked to mito-
chondrial disorders. We newly confirmed 3 mitochondria-related genes (MRPS23, QRSL1, and
PNPLA4) as causative genes of mitochondrial respiratory chain complex deficiencies. Three
patients (2.1%) harbored mutations in genes known to cause monogenic diseases (MECP2 and
TNNI3). Intriguingly, 4 patients (2.8%) had pathogenic chromosomal deletions previously
linked to other disorders (6q24.3-q25.1, 22q11.21, and 17p12) but not linked to mitochondrial
respiratory chain complex deficiencies.
In 53 (37.3%) patients, we identified and designated candidate genes or loci as prioritized
variants of unknown significance (pVUS) because these variants have possibilities to be patho-
genic but have insufficient evidence to support a disease linage. The current lack of functional
validation for linking these genes with mitochondrial disorders led us to classify these variants
as inconclusive with respect to pathogenicity (S3, S4 and S5 Tables). The remaining 40 (28.2%)
patients lacked prioritized nuclear variants, mtDNA variants, and chromosomal abnormalities.
Fig 2. Breakdown of 142 patients categorized by the type of mutations/variants in comprehensive
genomic analysis. Numerals in each colored box indicate the number of patients. Patients harboring
multiple variants were assigned to each box on the basis of the highest priority variant in all cases.
doi:10.1371/journal.pgen.1005679.g002
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New genetic diagnoses for cases with previously established nuclear
disease genes
Twenty-two genes were prioritized in 31 patients (Table 1). Of these, 29 patients harbored 41
disease-causing mutations in 20 genes known to cause OXPHOS disease: ACAD9, BOLA3,
COQ4, COX10, EARS2, ECHS1, GFM1, GTPBP3, KARS,MPV17, NDUFA10, NDUFAF6,
NDUFB11, NDUFS4, RARS2, RRM2B, SCO2, SUCLA2, TAZ, and TUFM. All such mutations
were confirmed through Sanger sequencing and haplotype phasing. In particular, 8 patients
had homozygous mutations, 19 had compound heterozygous mutations, and 2 had hemizy-
gous mutations. Of the 41 mutations, 37 were novel and 4 were reported as pathogenic in the
Human Gene Mutation Database[10] (HGMD, professional version 2013.10).
BOLA3, which plays an essential role in iron–sulfur cluster production, was mutated in 4
unrelated patients with severe lactic acidosis and combined respiratory chain complex deficien-
cies (MIM 614299). Three of these patients (Pt045, Pt268, and Pt314) exhibited multiple organ
failure; Pt268 and Pt314 had hypertrophic cardiomyopathy, and Pt045 developed seizures. All
4 patients exhibited decreased complex II activity and harbored the c.287A>G (p.H96R) muta-
tion. Pt314 and Pt286 patients showed clear long contiguous stretches of homozygosity
(LCSH) (2.8 Mb, 3.2 Mb respectively) around this p.H96R mutation. Pt268 also showed a short
contiguous stretch of homozygosity (0.3 Mb). This homozygous region encompassing BOLA3
was shared between these unrelated individuals. Sanger sequencing identified the parents for
these three patients as heterozygous carriers of this mutation. No p.H96R carriers were found
in NHLBI GO Exome Sequencing Project (ESP6500), and 1 Japanese carrier in 1000 Genomes
Project (1KG) was found. We screened for mutations that violated the Hardy–Weinberg prin-
ciple and only identified the p.H96R mutation. These results suggest that p.H96R is common
in the Japanese population and has originated from a single founder (S5 and S6 Figs).
NDUFAF6, which plays an important role in complex I assembly, was mutated in 4 unre-
lated patients: Pt101, Pt512, and Pt598 exhibited regression, whereas Pt330 exhibited muscle
atrophy. All patients had complex I deficiency (MIM 256000). Pt101 shared 1 allele with Pt512
and another with Pt598. Pt330 harbored homozygous mutation c.820A>G (p.R274G) located
in 1.3 Mb LCSH. Sanger sequencing identified the parents as heterozygous carriers of this
mutation. Only 1 family was reported to harbor a mutation in this gene[18] (S7, S8 and S9
Figs).
NDUFB11, recently reported as causative gene for microphthalmia with linear skin defects
syndrome (MIM 300952) and encoding a complex I component, was mutated in Pt067, a boy
born to non-consanguineous parents under conditions of intrauterine growth restriction; this
patient presented with heart failure, respiratory failure, complex I deficiency, and lethal infan-
tile mitochondrial disorder (LIMD). He harbored a hemizygous de novomutation, c.361G>A
(p.E121K), and there was no NDUFB11 protein expression in his fibroblasts (S10 Fig). Because
the p.E121 residue is highly conserved in this gene, we performed functional in vivo assays
using a dndufb11-knockdown Drosophilamodel (S11 Fig); compared with controls, the mean
lifespan was significantly reduced and the metabolic rate was lower in knockdown flies. Blue-
native polyacrylamide gel electrophoresis (BN-PAGE) analysis showed a loss of complex I
assembly, and lactate and pyruvate levels were increased in the knockdown flies. The in vivo
dndufb11-knockdown Drosophila experiment further supported this conclusion. While prepar-
ing this manuscript, two girls harboring mutations in NDUFB11 with microphthalmia with lin-
ear skin defects were reported by van Rahden et al[19]. Our patient was a male and died 55 h
after birth. He presented with redundant skin but had no linear skin defects.
Pt459, a boy with lactic acidosis, developmental delays, hypertrophic cardiomyopathy, sei-
zure, and combined complex deficiencies (I and IV), harbored the compound heterozygous
A Comprehensive Genomic Analysis of Mitochondrial Disorder
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Pt045 LIMD CC Firm BOLA3 (NM_212552) c.225_229del:p.K75fs,
c.287A>G:p.H96R
Shared rare variant in four patients,
rescue
Pt268 LIMD CC Firm BOLA3 (NM_212552) c.287A>G:p.H96R, c.287A>G:p.
H96R
Shared rare variant in four patients,
rescue
Pt286 LD CC Firm BOLA3 (NM_212552) c.287A>G:p.H96R, c.287A>G:p.
H96R
Shared rare variant in four patients,
rescue
Pt314 CM CC Firm BOLA3 (NM_212552) c.287A>G:p.H96R, c.287A>G:p.
H96R
Shared rare variant in four patients,
rescue
Pt113 LIMD CC Firm COQ4 (NM_016035) c.718C>T:p.R240C, c.421C>T:
p.R141X
Rescue; patient is included in the
study by Brea-Calvo et al[11]
Pt223 CM CC Firm COX10 (NM_001303) c.862G>A:p.G288R,
c.1259C>T:p.P420L
Rescue









Known; patient is included in the study
by Haack et al[12]




Known; patient is included in the study
by Haack et al[12]
Pt112 HD CC Firm GFM1 (NM_024996) c.170C>A:p.S57Y, c.748C>T:p.
R250W
Known[13]




Patient is included in the study by
Kopajtich R. et al[14]
Pt459 MC CC Firm KARS (NM_005548) c.1343T>A:p.V448D, c.953T>C:
p.I318T
Rescue
Pt339 HD (MTDPS) CC Firm MPV17 (NM_002437) c.293C>T:p.P98L, c.376-1G>A Known[15], mtDNA decreased to
20.5% in hepatic tissue










Independent rare variant in two
patients (c.805 C >G), rescue




Independent rare variant in two
patients (c.371 T >C)




Independent rare variants in two
patients (c.371T>C, c.805C>G),
segregation









Rescue, de novo, functional assay





Pt222 NLIMD CIV Firm RARS2 (NM_020320) c.1321C>T:p.L441F,
c.1306G>T:p.D436Y
Segregation











A Comprehensive Genomic Analysis of Mitochondrial Disorder
PLOS Genetics | DOI:10.1371/journal.pgen.1005679 January 7, 2016 6 / 31
mutations c.1343T>A (p.V448D) and c.953T>C (p.I318T) in KARS. KARS is a lysyl-transfer
RNA synthetase that produces 2 proteins that localize to the cytosol and mitochondria. A
cDNA complementation assay revealed that mitochondrial KARS successfully rescued the
enzyme defect, but not cytosolic form (S12 Fig). Detailed information and evidential support
for other known genes are described in S1 Text.
Newly identified mutations in mitochondria-related genes
Five (MRPS23, C1QBP1, ALAS2, SLC25A26, QRSL1) genes were identified as novel candidate
genes (Tables 2 and S3). These genes were previously reported links to mitochondrial function
but not mitochondrial respiratory chain complex deficiencies. Of these, we obtained patho-
genic support for mutations inMRPS23 and QRSL1. In addition, candidate genes that have no
evidence of functional involvement in current mitochondrial biology are good targets for
underlying novel mitochondrial biological functions. In one such case, we identified PNPLA4
as a novel causative gene for mitochondrial respiratory chain complex deficiencies and proved
its mitochondrial localization for the direct evidence of mitochondrial functions. The support-
ive evidence included (i) the identification of independent mutations in candidate genes in
unrelated individuals with exquisitely similar phenotypes, (ii) rescue of patients’ cellular phe-
notypes in a cDNA complementation assay, and (iii) identification of a de novomutation in
the candidate gene. Other pVUS for candidate genes are shown in S3 Table.
A component of the highly conserved mitochondrial ribosome small subunitMRPS23[22]
was mutated in Pt276, a boy with hepatic disease and combined respiratory chain complex
deficiencies. In this patient, enzyme activities in complexes I and IV were decreased by 28%
and 14% of the normal fibroblastic values, respectively. The patient was born to a non-consan-
guineous family. However, high-density oligonucleotide array analysis identified an approxi-
mately 500 kb contiguous stretch of homozygosity encompassingMRPS23. No other candidate
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Known[17], LCSH, no deletion
detected by array
Pt634 NLIMD CC Firm TAZ (NM_000116) c.36_57del:p.12_19del
(hemizygous)
NDP
Pt559 NLIMD CIV Firm TUFM (NM_003321) c.440T>A:p.L147H, c.440T>A:p.
L147H
Segregation










Pt001 LIMD CC pVUS PC (NM_022172) c.1822G>A:p.G608R,
c.2120C>T:p.T707M
N.A.
All listed variants were conﬁrmed by Sanger sequencing of gDNA or cDNA. GERP scores of all listed variants, except for EARS2 (c.319C>T), were >2.5.
CI, complex I deﬁciency; CIV, complex IV deﬁciency; CC, combined complex deﬁciencies; CM, cardiomyopathy; HD, hepatic disease; LD, Leigh's
disease; LIMD, lethal infantile mitochondrial disorder; MC, mitochondrial cytopathy; ND, neurodegenerative disorder; NLIMD, non-lethal infantile
mitochondrial disorder; de novo, conﬁrmed de novo variant by trio-based sequencing; known, known disease variant; NDP, no detectable protein; LCSH,
long contiguous stretches of homozygosity from high-density oligonucleotide array; segregation, variant segregates with disease in family; N.A., not
available.
doi:10.1371/journal.pgen.1005679.t001
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c.119C>G (p.P40R) mutation inMRPS23 (NM_016070) (Figs 3A and S13). Sanger sequencing
identified the parents as heterozygous carriers of this mutation. A complementation assay res-
cued the defect in complexes I and IV (Figs 3B and S13) and restored mitochondrial 12S
rRNA/16S rRNA expression (Fig 3C).
Pt250, a girl with tachypnea, hypertrophic cardiomyopathy, adrenal insufficiency, hearing
loss, and combined respiratory chain complex deficiencies (I, II, III, and IV), harbored a homo-
zygous mutation c.398G>T (p.G133V) in QRSL1 (NM_018292) (Figs 3D and S14). Her older
brother, also ill, harbored the same homozygous mutation. Sanger sequencing identified the
parents as heterozygous carriers of this mutation. The high-density oligonucleotide array anal-
ysis identified a shorter 100 kb contiguous stretch of homozygosity encompassing QRSL1.
QRSL1 (hGatA) is a glutaminase that produces ammonia, which is then transferred to misacy-
lated Glu-charged tRNAGln to synthesize Gln-tRNAGln, which interacts with PET112L (hGatB)
and GATC (hGatC) to form a trimeric enzyme hGatCAB[23]. Additional screening also identi-
fied an independent patient (Pt860) harboring the compound heterozygous mutations
c.350G>A (p.G117E) and c. 398G>T (p.G133V) (Fig 3E). In vitro reconstitution of Gln-
tRNAGln formation using recombinant hGatCAB revealed strongly decreased transamidation
activity in both mutant (G117E or G133V) hGatA (Fig 3F).
PNPLA4 has both triacylglycerol lipase and transacylase activities. Pt712 is a boy who inher-
ited a hemizygous nonsense variant c.559C>T (p.R187X) in PNPLA4 (NM_001142389) from
his mother (Fig 4A and 4B). The colocalization of PNPLA4 and mitochondrial markers was
identified by immunofluorescence microscopic observation (Fig 4C). We confirmed PNPLA4
protein loss in the fibroblasts of this patient by qRT-PCR (Fig 4D), sodium dodecyl sulfate
(SDS)-PAGE/Western blotting (Fig 4E), and immunohistochemistry (Fig 4C). We found
reduced complex I, III and IV assemblies of Pt712 fibroblasts under low glucose medium
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Mitochondria-related genes




Rescue, functional assay, LCSH
Pt250 LIMD CC Firm QRSL1 (NM_018292) c.398G>T:p.G133V,
c.398G>T:p.G133V
Independent mutations in two patients,
segregation, functional assay




Mitochondrial localization, rescue, NDP
Known to cause monogenic disease genes
Pt053 MC CC Firm MECP2 (NM_004992) c.806delG:p.G269fs
(hemizygous)
De novo, known[20]





Pt827 CM CI Firm TNNI3 (NM_000363) c.575G>A:p.R192H
(heterozygous)
De novo, known[21]
All listed variants were conﬁrmed by Sanger sequencing of gDNA or cDNA. GERP scores of all listed variants were >2.5. CM, cardiomyopathy; EP,
enteropathy; HD, hepatic disease; LD, Leigh's disease; LIMD, lethal infantile mitochondrial disorder; MC, mitochondrial cytopathy; ND, neurodegenerative
disorder; CI, complex I deﬁciency; CIV, complex IV deﬁciency; CC, combined complex deﬁciencies; de novo, conﬁrmed de novo mutation by trio-based
sequencing; known, known disease variant; NDP, no detectable protein; LCSH, long contiguous stretches of homozygosity from high-density
oligonucleotide array; segregation, variant segregates with disease in family; splice, splicing defect observed in subject ﬁbroblast cDNA; N.A., not
available.
doi:10.1371/journal.pgen.1005679.t002
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conditions (Fig 4G). The expression of PNPLA4-V5 cDNA in the fibroblasts of Pt712 recov-
ered an amount of complex III and IV assemblies under low glucose medium conditions
(Fig 4F and 4G).
Fig 3. Newly identified causative genes via whole-exome sequencing analysis. (A) Family pedigrees of Pt276. (B andC) Complementation assay in
Pt276 fibroblasts and normal control (fHDF). Mitochondrial fractions were isolated from fibroblasts with established stable expression of MRPS23 using a
lentiviral expression system. Assembly levels and 12s rRNA stability were compared between control andMRPS23 expressing fibroblasts by BN-PAGE
/Western blotting (B) and qRT-PCR (C). fHDF: normal fetal human dermal fibroblast, RFP:mito-TurboRFP-V5, MRPS23:MRPS23-V5. Significance was
calculated in comparison with controls using Student's t-test (*; p < 0.01) (D and E) Family pedigrees of Pt250 (D) and Pt860 (E). (F) Time-course analysis of
in vitro amidotransferase activity of wild-type hGatCAB and mutated hGatCAB (hGatA p.G133V and p.G117A). In vitro amidotransferase assay was
performed following the protocol provided in Methods. [14C]-labeled Gln and Glu deacylated from aa-tRNAs were analyzed by TLC. Positions of Gln and Glu
on TLC were confirmed by [14C]Gln and [14C]Glu. Results of time-dependent amidotransferase activity are presented graphically in the lower panel.
doi:10.1371/journal.pgen.1005679.g003
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Mutations in genes known to cause other monogenic diseases
In our cohort, all patients showed mitochondrial respiratory chain complex deficiencies.
Intriguingly, we identified 3 cases having mutations in two genes that were previously reported
to cause other monogenic diseases but not linked to canonical mitochondrial disease. These are
MECP2 and TNNI3 (Table 2).
Pt053, a boy with complex I deficiency and seizures, diarrhea, arrhythmia, regression, respi-
ratory failure, liver dysfunction, and hearing loss, harbored the hemizygous de novomutation
c.806delG (p.G269fs, rs61750241) inMECP2 (NM_004992) (S15 Fig), a gene reported to cause
Rett syndrome (MIM 312750). We also identified another boy, Pt369, who harbored the hemi-
zygous de novomutation c.17_18insG (p.A6fs) inMECP2 (NM_001110792) (S15 Fig).
Pt827 was diagnosed with restrictive cardiomyopathy and complex I deficiency, and har-
bored the heterozygous de novomutation c.575G>A (p.R192H, rs104894729) (S16 Fig) in
TNNI3 (NM_000363); this exact mutation was reported to cause autosomal dominant familial
restrictive cardiomyopathy (MIM 115210). Electron microscopic examination also revealed
abnormally shaped mitochondria with concentric cristae (S16 Fig).
Known pathogenic copy number variations in patients with mitochondrial
respiratory chain complex deficiencies
It has long been thought that patients with mitochondrial respiratory chain complex defi-
ciencies rarely suffer chromosomal rearrangements but instead harbor mtDNA mutation,
deletion, and depletion or nuclear DNA mutation. We subjected our entire cohort to a high-
density oligonucleotide array to precisely evaluate the presence of any copy number varia-
tions (CNVs) of>100 kb. Intriguingly, we identified 13 patients (9.2%) harboring rare CNVs
(Tables 3 and S5).
Pt369 and Pt657, 2 boys with complex IV deficiency from independent families, harbored
similar deletions (1,429 and 1,387 kb) in chromosome 17p12. These 17p12 deletion disrupted
the last 2 exons of COX10 in both patients (Fig 5A). This region causes hereditary neuropathy
with liability to pressure palsies (HNPP) (MIM 162500). Whole exome analysis of Pt657
revealed an additional mutation c.683G>A (p.R228H) on the remaining allele of COX10 (Fig
5B and 5C). Notably, p.R228 is highly conserved among species. The PolyPhen2 and SIFT algo-
rithms predicted this mutation as “probably damaging. In both patients, fibroblastic COX10
mRNA expression was reduced (Fig 5D). The complementation study using wild-type COX10
confirmed recovery of the complex IV deficiency in Pt657 (Fig 5E, 5F and 5G). Taken together,
we concluded that Pt657 is a primary mitochondrial disorders. In Pt369, we concluded that de
novo frameshift insertion mutation inMECP2 as a primary causative based on phenotype
information, and classified 17p12 as pVUS.
Fig 4. The effect of PNPLA4 variant onmitochondrial function. (A andB) Family pedigrees of Pt712. A hemizygous variant c.298C>T (p.R100X) in
PNPLA4 (NM_001172672) was found in Pt712. The healthy elder daughter and elder brother harbored wild-type PNPLA4. The c.298C>T variant was
inherited from the mother by Pt712. (C) Immunofluorescence microscopy confirmed the colocalization of PNPLA4 (green) with MitoTracker Orange
CMTMRos (red). Pt712 cells showed a decrease in the endogenous PNPLA4 protein level. The lentiviral-mediated exogenous expression of PNPLA4-V5
also confirmed mitochondrial localization of PNPLA4. Scale bar, 100 μm. (D and E) PNPLA4mRNA and protein expression levels were determined by
quantitative real-time PCR and SDS-PAGE/Western blotting. PNPLA4mRNA (D) and protein (E) expression levels were apparently decreased in total cell
lysates of Pt712 fibroblasts. β-actin was used as a loading control. Significance relative to controls was calculated using Student’s t-test (*; p < 0.01). (F and
G) Complementation assay using Pt712 fibroblasts. (F) mito-TurboRFP-V5 and PNPLA-V5 proteins in the mitochondria of patient cells with stable
expression ofmito-TurboRFP-V5 or PNPLA4-V5 cDNA were detected by SDS-PAGE/Western blotting. HSP60 was used as a loading control. (G)
BN-PAGE/ Western blotting under high (4.5 g/l) and low (1.0 g/l) glucose medium conditions (abbreviated to HG and LG). In low glucose medium conditions,
BN-PAGE/ Western blotting analysis revealed complex IV deficiency in patient fibroblasts. Complementation with PNPLA4 restored the complex IV assembly
level in patient fibroblasts. RFP:mito-TurboRFP-V5, PNPLA4: PNPLA4-V5.
doi:10.1371/journal.pgen.1005679.g004
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We identified de novo 6q24.3-q25.1 deletions (S17 Fig) in Pt452 and Pt695, unrelated
patients who harbored congenital heart defects. This region has been associated with the chro-
mosome 6q24-q25 deletion syndrome (MIM 612863) and congenital heart defects[24].
Pt587, a boy diagnosed with LIMD and complex IV deficiency, harbored a deletion in
22q11.21. This deletion, which has been linked to DiGeorge syndrome (DGS, MIM 188400)
and velo-cardio-facial syndrome (VCFS, MIM 192430), was confirmed as a de novomutation
in this patient (S17 Fig).
Discussion
We performed comprehensive genomic analyses, including whole mtDNA and exome
sequence analyses using high-throughput sequencing and CNV screening using high-density
oligonucleotide arrays, for 142 patients with childhood-onset mitochondrial respiratory chain
complex deficiencies. We ultimately identified 41 mutations, of which 37 were novel, in 20
genes that were previously reported to cause OXPHOS disease and 3 novel mitochondria-
related genes (MRPS23, QRSL1, and PNPLA4) as causative genes of mitochondrial respiratory
chain complex deficiencies. We also found 9 previously confirmed mtDNAmutations and
1 large mtDNA deletion. We further identified 2 genes known to cause monogenic diseases
(MECP2, and TNNI3) and 3 chromosomal aberration regions (17p12, 6q24.3-q25.1, and
22q11.21) in our cohort. Collectively, this study defined firm genetic diagnoses in 49 of the
142 patients (34.5%). While the overall diagnostic rates for major and minor subgroups were
similar (33.9% in the major subgroup and 36.4% in the minor subgroup), 35 out of 49 geneti-
cally diagnosed patients showed biochemical defects in their fibroblasts (71.4%), indicating a
much higher genetic diagnostic yield in patients with such cellular defects. This is the first
report to comprehensively assess patients diagnosed clinically and biochemically.
MRPS23 is a component of the small mitochondrial ribosome subunit (28S ribosome).
Mutations inMRPS16[25] andMRPS22[26] cause mitochondrial respiratory chain complex
deficiencies because of reductions of 12S rRNA, a 28S ribosome component. One patient
exhibited a reduced 12S rRNA/16S rRNA ratio that was restored in a complementation study.
This was the first case ofMRPS23-induced mitochondrial respiratory chain complex
deficiencies.












Pt452 CM CIV Firm 6q24.3-q25.1 1,675 De novo (Paternal) Congenital heart defects,
nonsyndromic, 2
Pt695 HD CI Firm 6q24.3-q25.1 1,675 De novo (Paternal) Congenital heart defects,
nonsyndromic, 2
Pt369 ND CIV pVUS 17p12 1,429 Paternal Hereditary neuropathy with liability to
pressure palsies
Pt657 MC CIV Firm 17p12* 1,387 N.A. Hereditary neuropathy with liability to
pressure palsies
Pt587 LIMD CIV Firm 22q11.21 2,691 De novo (Maternal) DiGeorge syndrome/Velocardiofacial
syndrome
CM, cardiomyopathy; HD, hepatic disease; LIMD, lethal infantile mitochondrial disorder; MC, mitochondrial cytopathy; ND, neurodegenerative disorder; CI,
complex I deﬁciency; CIV, complex IV deﬁciency; de novo, conﬁrmed de novo mutation by trio-based copy number analysis; *The missense mutation in
COX10 was found in the other allele; N.A., not available.
doi:10.1371/journal.pgen.1005679.t003
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Fig 5. Chromosomal microdeletions contribute to mitochondrial respiratory chain complex
deficiencies. (A) The 17p12 deletion was detected by high-density oligonucleotide arrays. This
heterozygous deletion of 17p12 involved the last 2 exons of COX10. (B andC) Family pedigrees of Pt657 and
Pt369. In Pt369, the 17p12 deletion was paternally inherited (C). Eu means uninformative DNA test. (D)
Analysis of endogenous COX10mRNA expression relative to that in normal cells (fHDF and NHDF; Normal
neonatal human dermal fibroblast); Pt223 harbored compound heterozygous non-synonymous mutations in
COX10. TheCOX10 expression in Pt369 and Pt657 was decreased by 50%. (E–G) Wild typeCOX10 cDNA
rescue of complex IV assembly and activity in Pt657 fibroblasts. Mitochondria were isolated from control or
Pt657 fibroblasts, and mitochondrial respiratory complex assembly was analyzed by BN-PAGE andWestern
blotting. Wild-type COX10-V5 cDNA expression rescued complex IV assembly in Pt657 fibroblasts (E).
Mitochondrial TurboRFP-V5 (RFP) and COX10-V5 (COX10) were detected in control and Pt657 fibroblasts
(F). Mitochondrial respiratory chain complex activities were measured twice. Compared with TurboRFP-V5
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QRSL1 (GatA) is involved in Gln-tRNAGln formation. No mitochondrial glutaminyl-tRNA
synthetase (GlnRS) has been identified in mammals; therefore, Gln-tRNAGln synthesis was
proven to occur via an indirect pathway[23]. In particular, mt tRNAGln is first misaminoacy-
lated by mt glutamyl-tRNA synthetase (GluRS) to form Glu-tRNAGln, followed by transamida-
tion to form Gln-tRNAGln. This transamidation is processed by a human homolog of the Glu-
tRNAGln amidotransferase hGatCAB heterotrimer. We clearly showed that mutations in
QRSL1 (GatA), a component of hGatCAB, observed in our patients were associated with severe
transamidation activity defects.
PNPLA4 encodes a calcium-independent phospholipase A2η (iPLA2η) that acts as an acyl-
glycerol and retinol transacylase, triglyceride hydrolase. PNPLA4 has never been reported to
associate with the mitochondria. Nine patatin-like phospholipase domain-containing proteins
(PNPLA1–9) are encoded in the human genome. iPLA2γ (PNPLA8) is known to be involved
in cardiolipin biosynthesis and mitochondrial respiration[27,28]. Recently, mutations in
human PNPLA8 identified in a young girl with a suspected mitochondrial myopathy[29]. She
presented with progressive muscle weakness, hypotonia, seizures, poor weight gain, and lactic
acidosis. A deficiency in iPLA2β (PNPLA9) was previously shown to cause abnormal phospho-
lipid metabolism and mitochondrial defects in mice[30]. Here we demonstrated the mitochon-
drial localization of iPLA2η using immunohistochemistry and restored of the amount of
complex IV in Pt712 fibroblast cells via the exogenous expression of wild-type PNPLA4. We
assume that PNPLA4 is also required for mitochondrial phospholipid metabolism and respira-
tory chain function.
Although all patients were diagnosed with mitochondrial respiratory chain complex defi-
ciencies, we identified 2 disease-causing genes and 2 pathogenic CNVs known to cause other
genetic disorders in our cohort. These includedMECP2, TNNI3, 6q24.3-q25.1 deletion, and
22q11.21 deletion. Because all of these patients had complex II activities within the normal
range (percentage of protein and citrate synthase ratio), we concluded that their defects were
not artefactual[31,32]. Because these genes and loci are not directly linked to the respiratory
chain complex, we consider the mitochondrial respiratory chain complex deficiencies are
caused by secondary. Pt053, Pt369, and Pt827 were classified as having major ETC reductions
in affected tissues, whereas Pt452, Pt695, and Pt587, harbored deletions are all classified as
minor. The fact these heterozygous deletions are all classified as minor suggests that the mito-
chondrial defects in these patients might be caused indirectly through haploinsufficiency.
Because Pt053 and Pt369 harboredMECP2mutations known to cause Rett syndrome, we
re-evaluated the phenotypes of both patients and found phenotypes that overlapped with Rett
syndrome characteristics (seizures, microcephaly, cerebral atrophy, and hearing loss). Previous
studies also reported mitochondrial dysfunction in Rett syndrome[33,34]. Although Pt827 was
enrolled with a diagnosis of mitochondrial disease, after comprehensive genomic analyses, the
clinical diagnosis was changed to cardiomyopathy, familial restrictive (OMIM: 115210) caused
by a mutation in TNNI3. Jia et al reported a link between Tnni3 and mitochondrial dysfunction
using knockout mice [35].
Two independent patients from our cohort showed 6q24.3-q25.1 deletions. Pt452 exhibited
a phenotype similar to that of cases reported cases in OMIM (MIM 612863). Pt695 presented
with respiratory distress and a congenital heart defect. We classified these patients as having
chromosome 6q24-q25 deletion syndrome. The enrichment of this deletion supports the sug-
gested link with mitochondrial dysfunction. Pt587 was difficult to diagnose based on clinical
expressing Pt657 fibroblasts, expression of wild-type COX10-V5 in Pt657 fibroblasts resulted in a significant
increase in complex IV activity (G).
doi:10.1371/journal.pgen.1005679.g005
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information, because he did not have the facial anomalies and cleft palate characteristic of
DGS/VCFS. The 22q11.21 deletion includes some mitochondria-related genes (PRODH,
SLC25A1,MRPL40, TXNRD2, COMT, TANGO2, ZDHHC8, and AIFM3), suggesting a link
between this deletion and mitochondrial dysfunction. The inclusion of a patient with features
of DGS/VCFS and complex I deficiency in a study by Calvo et al[36] also indicates a link with
mitochondrial dysfunction.
With these in mind, we should be mindful that some patients with mitochondrial respira-
tory chain complex defects will have mutations in genes apparently unrelated to mitochondrial
functions.
Previous reports of mitochondrial disorders can be classified as either target resequence
studies[37,38,7] or whole exome approaches[39,40,41]. When comparing target resequencing
groups, our approaches are advantageous for the identification of mutations in other disease-
causing genes, and the detection of chromosomal aberrations. WES groups[40,41] and our
group detected pathogenic mutations in genes not linked to mitochondrial disorders. When
comparing WES groups, our approaches are advantageous in terms of mtDNA sequencing and
chromosomal aberration analysis. Our analysis could detect mtDNA heteroplasmy using long-
range PCR-based sequencing and also revealed established pathogenic chromosomal deletions.
Accordingly, we identified a composite combination of COX10 SNV and 17p12 deletion
(Pt657). Previous WES and target exome reports achieved molecular diagnoses in 20%–60% of
their cohorts. A precise comparison of overall diagnostic rates with previous studies is difficult,
given the existence of several biases that affect the diagnostic rate, including prior mtDNA/
nDNA genetic screening, population characteristics, phenotyping accuracy, and study design.
In particular, the reports by Taylor et al[40] described a high rate of diagnosis (approximately
60%) in their cohort, although their patient group appeared to be enriched by consanguineous
families (12 of 28 diagnosed cases). The report by Wortmann et al[41] described a rate of diag-
nosis (38%) similar to ours. In our study, we emphasized functional analyses to conclude dis-
ease causality against pVUS and attempted to present molecular evidence of pathogenicity;in
contrast, some previous studies lacked sufficient molecular evidence of pathogenicity. We des-
ignated the variants without any molecular evidence of pathogenicity as pVUS, even when the
gene had been reported as a causal gene for mitochondrial disorders. We consider molecular
evidence to be indispensable for a conclusive firm genetic diagnosis.
We found that approximately 28.2% of patients lacked any prioritized variants. We likely
missed pathogenic mutations in these unresolved cases for the following reasons, as discussed
in a report by Calvo et al[6]: first, we may have missed pathogenic mutations because of a lack
of sensitivity from low sequence coverage. Second, pathogenic mutations may be located in
uncovered genomic regions (e.g., uncovered exons, introns, or regulatory regions not targeted
by whole exome platforms). Third, our filtering strategy may have filtered true pathogenic
mutations, although some were recovered by manual curation. Fourth, the hereditary assump-
tion may be wrong. More dominant-acting cases may exist. Digenic/polygenic inheritance may
also exist beyond our expectation.
In conclusion, for suspected mitochondrial disorders, comprehensive analyses such as those
in this study are worthwhile. We expanded the clinical disease spectrum and revealed the
genetic landscape of this disorder.
Methods
Patient information
In total, 142 patients with childhood-onset and enzymatically diagnosed mitochondrial respi-
ratory chain complex deficiencies were enrolled in this study. Informed consent was obtained
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from the patients and their families before participation in the study. Patients with suspected
mitochondrial respiratory chain complex deficiency were referred to the Saitama Medical Uni-
versity Hospital and Chiba Children’s Hospital in Japan from 2007 to 2013. The inclusion cri-
terion was a biochemical diagnosis of mitochondrial respiratory chain complex activity in a
clinically affected tissue (skeletal muscle, liver, or heart) or fibroblasts in patients younger than
at the age of 15 years. Patients with known nuclear or mtDNA mutations at the time of recruit-
ment were excluded. The 142 included patients had not received a prior molecular diagnosis,
despite varying degrees of exposure to genetic testing. This cohort included 3 non-Japanese
cases: Pt346 (father, American; mother, Japanese), Pt298 (Brazilian), and Pt223 (Vietnamese).
Enzyme activity[42] was measured on the basis of spectrophotometric enzyme assays using
fibroblasts from patient’s skin or biopsy specimens from diseased organs of patients with clini-
cally suspected mitochondrial respiratory chain disorders[43]. All enrolled patients in this
study had biochemical mitochondrial respiratory chain complex deficiencies; the enzymatic
diagnoses are shown in S1A Fig. In brief, complex I deficiency was most common (61 patients,
43.0%), followed by (in decreasing order of prevalence) combined respiratory chain complex
deficiencies (46 patients, 32.4%), complex IV deficiency (27 patients, 19.0%), MTDPS (5
patients, 3.5%), and complex III deficiency (3 patients, 2.1%); no patients exhibited complex II
deficiency. Diagnoses of mitochondrial respiratory chain complex deficiencies were assessed as
“major” or “minor” on the basis of biochemical complex activity. Based on the Bernier criteria,
severity was defined as major (<20% in a tissue,<30% in a fibroblast cell line, or<30% in2
tissues) or minor (<30% in a tissue,<40% in a fibroblast cell line, or<40% in2 tissues) in
accordance with the residual mean citrate synthase or complex II activities relative to those of
normal controls (S1B Fig). The distribution of age of onset of these patients was as follows:
45.7% (65 patients) before 1 month, 19.7%(28 patients) within 1–6 months, 19.7%(28 patients)
within 6–24 months, 12,7% (18 patients) within 2–10 years, and 2.1% (3 patients) within 10–
15 years (S1C Fig). The clinical diagnoses of 142 patients are also shown in S1D Fig. The most
common diagnosis was mitochondrial cytopathy (27 patients, 19.0%), followed by Leigh’s dis-
ease (25 patients, 17.6%), LIMD (23 patients, 16.2%), sudden unexpected death (17 patients,
12.0%), non-lethal infantile mitochondrial disorder (NLIMD) (16 patients, 11.3%), cardiomy-
opathy (11 patients, 7.7%), hepatic disease (11 patients, 7.7%), enteropathy (6 patients, 4.2%),
neurodegenerative disorder (4 patients, 2.8%), and short stature (2 patients, 1.4%). The male:
female ratio was 76:66. There were no consanguineous relationships among our cohort.
Detailed clinical characteristics are described in S1 Table.
DNA and RNA extraction and cDNA preparation
DNA was isolated from cultured fibroblast cells using the QIAamp DNA Blood mini Kit (QIA-
GEN). Blood genomic DNA was isolated by phenol–chloroform extraction according to the
standard protocol. Total RNAs were purified from HEK293FT cells, fibroblast cells using the
SV Total RNA Isolation System (Promega). cDNAs were synthesized from total RNAs using
ReverTra Ace (Toyobo). Total RNA was extracted from flies using TRIzol reagent (Invitrogen),
and RNA was reverse transcribed by SuperScript VILO transcriptase (Invitrogen).
mtDNA sequencing and alignment and variant prioritization
To avoid the contamination of mitochondrial-origin nuclear genome sequences [44]
(NUMTs), a long-range mtDNA polymerase chain reaction (PCR) method was used in this
study. DNA were extracted from patients skin fibroblast cells. These DNAs were checked for
large-scale mtDNA rearrangements and subjected to large mtDNA deletion mapping using
long-range PCR with amplicon 1 (rCRS 619–8988) and amplicon 2 (rCRS 8749–895) primers;
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50-GACGGGCTCACATCACCCCATAA-30 and 50-GCGTACGGCCAGGGCTATTGGT-30
for amplicon 1, and 50-GCCACAACTAACCTCCTCGGGCTCCT-30 and 50-GGTGGCT
GGCACGAAATTGACC-30 for amplicon 2.
Indexed PCR fragment libraries were prepared from patient mtDNA using the Nextera XT
DNA Sample Prep Kit (Illumina) according to the manufacturer’s protocol. Sequencing library
concentrations were estimated using a library quantification kit (Kapa Biosystems). Sequencing
was performed with 150-bp paired-end reads on MiSeq (Illumina). Read alignments to the
1000 Genomes Project phase II reference genome (hs37d5.fa), which contains rCRS sequences,
were performed with the Burrows–Wheeler Aligner[45] (BWA, version 0.7.0). PCR duplicate
reads were removed using Picard (version 1.89); non-mappable reads were removed using
SAMtools[46] (version 0.1.19). After filtering out those reads, we applied the Genome Analysis
Toolkit[47] (GATK version 2.4-9-nightly-2013-04-12-g3fc5478) base quality score recalibra-
tion and performed SNP and INDEL discovery (UnifiedGenotyper). Confirmed pathogenic
mutations and reported variants in MITOMAP and mtDNA deletions detected through refer-
ence-based alignment with BWAmapping were prioritized (S4 Table).
mtDNA de novo assembly
De novomtDNA sequence assembly was performed using SPAdes (version 3.0.0)[48] with iter-
ations over values of 3 kmer sizes (k = 75, 95, and 115). Each assembly was aligned to the mito-
chondrial genome sequence of hs37d5.fa using BLASTN (version 2.2.29+) with default settings
and was manually inspected to identify aberrations (deletions, duplications, and
rearrangements).
Validation of large mtDNA deletion
A large mtDNA deletion in Pt334 was validated using long-range PCR with primers 50-GCCA
CAACTAACCTCCTCGGGCTCCT-30 and 50-GGTGGCTGGCACGAAATTGACC-30. The
mtDNA was also sequenced (using primers 50-ACTACCACTGACATGACTTTCCAA-30 and
50-TGTTGTTTGGATATATGGAGGATG-30 for amplification and 50-CTTATCCAGTGAA
CCACTATCACG-30 for sequencing) closer to the breakpoint as described above.
Quantitative PCR for MTDPS diagnosis
Quantitative PCR[49] was used to determine whether mtDNA depletion was present in
patients with decreased activity levels for multiple respiratory chain enzymes (mtDNA gene
MT-ND1 was compared against a nuclear gene [CFTR exon 24]). A diagnosis of MTDPS was
made when the relative copy number ratio of mtDNA to nuclear DNA was less than 35% of
that in healthy control tissues in 4 independent experiments.
Quantitative reverse transcription PCR
Quantitative reverse transcription PCR (qRT-PCR) was performed for the analysis of mRNA
(NDUFB11, TTC37, and PNPLA4) and mitochondrial rRNA expression[50]. Primers were
designed with the Primer3 software[51]. Primer sequences used in the qRT-PCR analysis are
listed in S6 Table. qRT-PCR of cDNA extracted from human cells was performed using SYBR
Premix Ex Taq (Takara), Power SYBR Green PCRMaster Mix (Life technologies), and
Mx3000P (Agilent Technologies). The relative mRNA concentration was normalized to the
average of two housekeeping genes (β-actin and GAPDH). qRT-PCR of cDNA extracted from
flies was performed using SYBR Premix Ex Taq II (Takara) and Chromo 4 Four-Color Real-
Time System (Bio-Rad). Results were normalized to the rp49mRNA level.
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Whole exome sequencing and variant calling pipeline
Indexed genomic DNA (gDNA) libraries were prepared from patient gDNA, and exomes were
captured using TruSeq (Illumina), SeqCap EZ (Roche AG, Basel, Switzerland), and SureSelect
(Agilent Technologies) exome enrichment kits according to the manufacturers’ protocols.
Sequencing library concentrations were estimated using a library quantification kit (Kapa Bio-
systems). Sequencing was performed using 100-bp paired-end reads on a HiSeq2000 or GAIIx
(Illumina). The precise exome platforms used in this study are listed in S2 Table. The raw
sequence read data passed the quality checks in FASTQC (see URLs). Read trimming via base
quality was performed using Trimmomatic[52]. Read alignment was performed with BWA,
the hs37d5 reference genome, Picard, and SAMtools as described above. GATK was also used
for insertion and deletion realignment, quality recalibration, and variant calling. Detected vari-
ants were annotated using both ANNOVAR (version 2013Feb21)[53] and custom ruby scripts.
Prediction scores were obtained from dbNSFP[54].
Whole exome variant prioritization
Variants that passed quality control were prioritized according to the following strategies (S2 Fig).
We only retained variants predicted to modify protein function; these included nonsense, splice
site, coding indel, or missense variants. We removed variants with minor allele frequencies
(MAFs) of>1.0% for dbSNP 137 without knownmedical impact (allele frequencies were extracted
from common_no_known_medical_impact_20130808.vcf.gz),>0.1% for ESP6500 (provided by
ANNOVAR program) database,>1.0% for 1KG (these data are based on a phase 1 release v3
called from the 20101123 alignment and provided by ANNOVAR),>0.1% for the Exome Aggre-
gation Consortium (ExAC, accessed on December 2014), and>0.4% in HGVD (contains genetic
variations determined by exome sequencing of 1,208 individuals in Japan; see URLs). Variants that
were too common among cases (10 alleles) were also excluded. Careful inspection of the reads
using the Integrative Genomics Viewer[55,56] and NextCODE clinical sequence analyzer (see
URLs) excluded doubtful genes from prioritized candidate genes when 2 sequence variants were
present in the same read (or read-pair). Variants that appeared to be mapping artifacts (called by
suspicious reads or end positions of NGS reads) were also excluded through a manual inspection
of NGS reads. Variants located within segmental duplication regions were excluded. In addition to
these filters, Sorting Intolerant From Tolerant (SIFT) scores> 0.15 and Genomic Evolutionary
Rate Profiling (GERP) scores< 2.5 were used for further prioritization. We also excluded variants
inconsistent with a recessive mode of inheritance. Two (or more) variants on a single haplotype as
identified by Sanger sequencing were also excluded. Finally, we filtered remaining genes based on
MAF and genotype information in the 1,070 whole-genome reference panel database (1KJPN)
constructed in the TohokuMedical Megabank Project in Japan (http://ijgvd.megabank.tohoku.ac.
jp/). The details of the project and analysis are described in the 1KJPN literature[57]. To recover
true mutations that were filtered out using current pipeline applying stringent conditions, we also
applied this pipeline without a segmental duplication filter, SIFT filter, or GERP filter, followed by
focusing on mitochondria-related genes.
Prioritized gene enrichment analysis
Enrichment analysis was conducted to evaluate our exome pipeline and included 128 cases and
175 ethnically matched healthy controls whose sequence reads exceeded 50 million; these were
adjusted to 50 million reads per individual. We used a simplified exome analysis pipeline that
did not include a manual inspection step, Sanger sequencing validation step, and 1KJPN filter-
ing step. We also omitted the HGVD filtering step because these control data were included in
the HGVD samples. The other steps were the same as those described above for the exome
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analysis pipeline. After processing the controls and cases, we calculated the percentage of indi-
viduals harboring prioritized genes. Comparisons of the percentages of controls and cases on
the basis of known disease genes and mitochondria-related genes are shown in S3A Fig. To
consider the background rate of this simplified pipeline, we also evaluated enrichment using
randomly selected 908 genes with no strong mitochondrial relationships in their annotations.
The gene set was generated 1000 times via random selection from all genes after excluding
those known to cause OXPHOS disease and those listed in MitoCarta[18]. The results plus
standard deviations are shown in S3B Fig.
Sequence validation and haplotype phasing
Prioritized variants were independently validated by Sanger sequencing. PCR products were
either directly sequenced using GENEWIZ, ABI 3130XL, and BigDye v3.1 Terminators
(Applied Biosystems) per the manufacturer’s protocols or sequenced after gel purification
using the MinElute Gel Extraction Kit (QIAGEN). Sequencing primers are listed in S7 Table.
All compound heterozygous variants described in the main text were confirmed on different
alleles (phased) using sequenced, cloned gDNA or cDNA derived from the patients’ fibroblasts.
Patients’ familial DNA was also sequenced for haplotype phasing when available. All informa-
tion about the experimentally confirmed localization of compound variants within a separate
allele is presented in S3 Table.
Multiple alignment with ClustalW
Amino acid sequences of orthologous genes were downloaded from the HomoloGene database
(see URLs). Amino acid sequence alignments were constructed with the ClustalW2 program[58].
Cell culture and cDNA rescue assay
Cells were cultured at 37°C and 5% CO2 in Dulbecco's modified Eagle’s medium (DMEM 4.5 g/l
glucose or 1.0 g/l glucose; Nacalai tasque) supplemented with 10%–20% fetal bovine serum. Nor-
mal neonatal human dermal fibroblasts (NHDFs; Takara) and normal fetal human dermal fibro-
blasts (fHDFs; Toyobo) were used as control fibroblast cells. Open reading frames (ORFs) of
candidate genes (ACAD9, BOLA3, COX10, KARS,MRPS23,NDUFA10,NDUFAF6, PNPLA4, and
TUFM) were PCR amplified from cDNA. Primer sequences used for cDNA cloning are listed in
S8 Table. ORFs and pTurboRFP-mito (TurboRFP fused to a mitochondrial targeting sequence
derived from the subunit VIII of human cytochrome C oxidase; Evrogen) were cloned into the
CS-CA-MCS lentiviral vector with a C-terminal V5 tag, CAG promoter for mammalian cell
expression, and blasticidin resistance using the In-Fusion HD Cloning Kit (Clontech Laboratories,
Inc.). Following this, 2 × 106 HEK293FT cells were seeded in 6-cm plates and co-transfected with
ViraPower Packaging vectors (pLP1, pLP2, pLP/VSVG; Invitrogen) and a pCA-CS-ORF(candi-
date gene)-blast vector. Transfection was performed using Lipofectamine 2000 (Invitrogen).
Transfection medium was replaced with fresh medium 24 h after transfection. Supernatant con-
taining the viral particles was collected 48 h after transfection and filtered through a 0.45 μm filter.
Patients’ skin fibroblasts were infected with the viral supernatant and 5 μg/ml polybrene (Sigma)
for 24–48 h. After 5–7 days, selection was initiated with 1–2 μg/ml blasticidin. After 1–3 months of
selection, mitochondria were harvested from the cells for enzyme assays or BN-PAGE.
Respiratory chain enzyme analysis
To prepare enriched mitochondria, cell pellets were resuspended in ice-cold MegaFb Buffer
(250 mM sucrose, 2 mMHEPES, 0.1 mM EGTA, pH 7.4) and homogenized with 20 strokes.
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The homogenates were centrifuged for 10 min at 600 g. Supernatants were centrifuged for an
additional 10 min at 14,400 g. Pellets were resuspended in 400 μl MegaFb buffer, and 200 μl ali-
quots were frozen and thawed 3 times for complex II + III and complex III assays and protein
estimation. The remaining samples were resuspended in hypotonic buffer (25 mM potassium
phosphate, pH 7.2, 5 mMMgCl2) for complex I, II, and IV, citrate synthase, and protein con-
centration assays and centrifuged for 10 min at 14,400 g. Pellets were resuspended in Hypo-
tonic Buffer and subjected to 3 freeze–thaw cycles. These samples were stored at −80°C prior to
enzyme assays. Respiratory chain enzyme activities were measured using cary300 (Agilent
Technologies) as described previously[42]. Complex I, II, II + III, III, and IV activities were
expressed as percentages of citrate synthase activity.
SDS-PAGE and BN-PAGE analyses
To isolate mitochondria, cell pellets were suspended in mitochondria isolation buffer A
(220 mMmannitol, 20 mMHEPES, 70 mM sucrose, 1 mM EDTA, pH 7.4, 2 mg/ml bovine
serum albumin, 1× protease inhibitor cocktail) and homogenized with 20 strokes on ice.
Homogenates were separated into cytosolic and nuclear fractions after centrifugation at 700 g
for 5 min at 4°C. The supernatants were centrifuged at 10,000 g for 10 min at 4°C. Mitochon-
drial pellets were rinsed twice with mitochondria isolation buffer B (220 mMmannitol, 20 mM
HEPES, 70 mM sucrose, 1 mM EDTA, pH 7.4, 1× protease inhibitor cocktail). Mitochondria
were isolated from adult flies as described previously[59]. Fifty flies were homogenized in 1 ml
of chilled mitochondrial isolation medium (MIM; 250 mM sucrose, 10 mM Tris pH 7.4,
0.15 mMMgCl2). The samples were centrifuged twice for 5 min at 1,000 g at 4°C to remove
debris. The supernatant was centrifuged again for 5 min at 13,000 g at 4°C.Mitochondrial pro-
tein levels were determined using a bicinchoninic acid (BCA) assay. For SDS-PAGE analyses,
enriched mitochondria and cell pellets were solubilized in M-PER Mammalian Protein Extrac-
tion Reagent (Thermo Fisher Scientific) and denatured for 30 min at 37°C. Prepared samples
were separated by electrophoresis on 8%, 10%, and 15% SDS-PAGE gels, depending on the size
of the detected protein. For BN-PAGE analyses, The NativePAGE Novex Bis-Tris Gel System
(Life Technologies) was used according to the manufacturer’s protocol. Mitochondrial frac-
tions were solubilized in NativePAGE sample buffer containing 0.5% Triton-X100 and sepa-
rated on 4%–16% NativePAGE gels. The BN-PAGE analyses of Drosophila were performed as
previously described[60]. Immunoblot analysis was performed as described previously[61].
Anti-NDUFA9 (Complex I), anti-70 kDa Fp Subunit (Complex II), anti-core 1 (Complex III),
anti-subunit 1 (Complex IV), and anti-V5 antibodies were purchased from Life Technologies.
Anti-Lamin A/C antibody was purchased from BD biosciences. Anti-HSP60, anti-NDUFA10,
anti-ACAD9, and anti-COX10 antibodies were purchased from Abcam, and anti-NDUFB11
antibody was purchased from Santa Cruz Biotechnology. Anti-TTC37 antibody was purchased
from ProteinTech. Anti-PNPLA4 (GS2) was purchased from GeneTex. Anti-tafazzin and anti-
α/β-tubulin antibodies were purchased from Cell Signaling Technology. Anti-β-actin antibody
was purchased from Sigma. Anti-MECP2 antibodies were purchased from Acris Antibodies
and Merck Millipore.
Localization studies of the PNPLA4 protein
Normal human dermal fibroblast cells and patient cells were seeded in a 35-mm glass-bottom
dish. Mitochondria were stained with 500 nMMitoTracker Orange CMXRos (Molecular
Probes) for 30 min in DMEM containing 10% fetal bovine serum. Cells were fixed with 4%
paraformaldehyde for 20 min and permeabilized by incubation in 0.2% Triton X-100. After
blocking with 3% bovine serum albumin, fluorescent staining was performed with rabbit anti-
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PNPLA4 antibody (GeneTex) or mouse anti-V5 antibody (Life Technologies) and secondary
Alexa Fluor 488 antibody (Molecular Probes) or secondary FITC antibody (Sigma). Cells were
visualized with a Leica TCS SP8 confocal microscope.
siRNA knockdown
For siRNA transfection, Lipofectamine RNAiMAX (Invitrogen) and 120 pmol of siRNA were
prepared according to the manufacturer’s instructions and directly added to a 10 cm culture
dish of NHDF fibroblasts. Mitochondria were isolated after 6 days, and the assembly levels of
respiratory chain complexes were analyzed using BN-PAGE and Western blotting. The Stealth
RNAi siRNA (Life Technologies) sequences used for NDUFB11 knockdown are as follows:
HSS147694 (#94), ACC CAG ACU CCC AUG GUU AUG ACA A; HSS147695 (#95), UCC
AAG AGC GUG GGA UGG GAU GAA A; HSS147696 (#96), CCU CUU CUC AGA GCA
CCU AAU UAA A. Stealth RNAi siRNA Negative Control, Med GC (cat no. 12935–300) was
used as the negative control. The Silencer Select RNAi siRNA (Life Technologies) used for
MECP2 knockdown are as follows: s8644 (#44), s8645 (#45), s8646 (#46). Silencer Select RNAi
siRNA Negative Control, No.2 (#2) (cat no. 4390847) was used as the negative control.
Fly strains and culture conditions
Flies were reared at 25°C in a standard glucose yeast agar medium containing propionic acid
and n-butyl p-hydroxybenzoate as mold inhibitors. arm-Gal4 was obtained from the Bloom-
ington Drosophila Stock Center. UAS-dndufb11 (NP15.6)-IR (5717) was obtained from the
Vienna Drosophila RNAi Center. UAS-GFP-IR (GFP-IR-2) was obtained from the National
Institute of Genetics Fly Stock Center.
Lifespan measurement
Newly eclosed flies were housed in a glass vial containing the standard glucose yeast medium
and were transferred to fresh media every 2 days; the numbers of dead flies were counted at the
time of transfer. At least 100 flies per genotype were used for experiments.
Behavioral analysis
Eight flies were placed in an 8-lane cell vial (1 cell; H 7 mm ×W 8 mm × D 70 mm) and
bumped to the bottom. Pictures were taken at 5 s after bumping and used to measure the dis-
tance climbed by each individual. For each sample, the average climbing activity of 10 trials
was determined.
Measurement of CO2 production
CO2 production was measured as described previously[62]. In brief, 10 adult flies were placed
in a 1-ml plastic syringe that contained a small amount of CO2-absorbent material (Soda lime),
which was connected to a 200-μl glass disposable micropipette. A small amount of black ink
was placed at the end of the micropipette as an indicator of CO2 production. The apparatus
was kept on a flat surface at 25°C, and measurement was initiated after 10 min. The amount of
CO2 produced by the flies was calculated according to changes in the air volume during 1 h of
measurement. Assays were performed at least 3 times per genotype.
Measurement of lactate and pyruvate
Lactate and pyruvate measurements were performed as described previously[63].
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Preparation of hGatCA complex bearing pathogenic mutation
The cDNAs for hGatA with C-terminal SBP-HA-tag and hGatC with C-terminal HA-tag were
cloned into pENTR/D-TOPO (Invitrogen). Each of the pathogenic point mutations (G117E
and G133V) was introduced into the hGatA gene in the entry clone by site-directed mutagene-
sis using PrimeSTAR HS DNA polymerase (Takara) with primers 50-GATCAGGGAGCTCT
ACTAATGGAAAAAACAAATTTAGA-30 and 50-TCATCTAAATTTGTTTTTTCCATT
AGTAGAGCTCCCTGATC-30 for G117E, and 50-GATCTGGGAGCACAGATGTTGTATTT
GGACCAGTTAAAAAC-30 and 50-GTTTTTAACTGGTCCAAATACAACATCTGTGCT
CCCAGATC-30 for G133V. The cDNAs for hGatA (WT, G117E or G133V) and hGatC were
transferred from each entry clone to pHAGE to generate the expression vector[64] by LR reac-
tion (Invitrogen).
HEK293T cells were co-transfected with lentiviral vectors (TAT, VSVG, RRE, or REV),
pHAGE-hGatA (WT, G117E or G133V) and pHAGE-hGatC. The transformants were cul-
tured at 37°C for 3 days. Cells were harvested and suspended in lysis buffer [50 mMHEPES-
KOH (pH 7.5), 200 mM KCl, 1 mM PMSF, 0.1% TritonX-100, 1 mM DTT, 2.5 mMMgCl2]
containing complete protease inhibitor cocktail (Roche) and were disrupted by sonication at
0°C. The hGatCA complex in the cell lysate was captured with streptavidin-Sepharose beads
(GE Healthcare) and was eluted from the beads with 4 mM of biotin according to the manufac-
turer’s instructions. The eluted hGatCA complex was subjected to SDS-PAGE, stained by
SyproRuby, and quantified with a FLA-7000 imaging analyzer (Fujifilm) with BSA as a stan-
dard. Recombinant hGatB was expressed in Escherichia coli and was purified as described pre-
viously[23].
[14C] glutamyl-tRNAGln preparation
As human mt GluRS strictly recognizes the post-transcriptional modification at the anticodon
first position (position 34) of human mt tRNAGln for glutamylation[23], in vitro-transcribed
human mt tRNAGln cannot be aminoacylated by human mt GluRS. However, Thermotoga
matritima nondiscriminating GluRS can efficiently glutamylate tRNAGln bearing unmodified
C at position 34[65]. We accordingly prepared in vitro-transcribed human mt tRNAGln with
C34 for glutamylation by T.maritima GluRS. Human mt tRNAGln with C34 was transcribed in
vitro by T7 RNA polymerase from the template DNA PCR-amplified with the synthetic DNAs
50-GCTAATACGACTCACTATATAGGATGGGGTGTGATAGGTGGCACGGAG-30, 50-AT
AGGTGGCACGGAGAATTCTGGATTCTCAGGGATGGGTTCGAT-30, and 50-TGGCT
AGGACTATGAGAATCGAACCCATCCCTGA-30, as described previously[66,67]. The ami-
noacylation reaction was performed at 37°C for 30 min in a mixture containing 50 mM
HEPES-KOH(pH 7.5), 20 mM KCl, 10mMMgCl2, 2 mM ATP, 1 mM DTT, 1 mM spermidine,
20 μM [14C]L-glutamine(9.36 GBq/mmol), 0.02 A260 unit of tRNA transcript, and 1.88 μM
T.maritima GluRS. The [14C]Glu-tRNAGln was extracted by phenol–chloroform treatment
under acidic conditions followed by ethanol precipitation. Residual ATP in the reaction was
removed using a Nap5 gel filtration column (GE Healthcare). A small part of the mixture was
spotted onto Whatman 3MM filter discs, followed by washing with 5% trichloroacetic acid,
and the radioactivity was measured by liquid scintillation counting.
Glutaminyl-tRNAGln formation by hGatCAB in vitro
In vitro reconstitution of Gln-tRNAGln formation by hGatCAB was performed as described
previously[23]. The reaction was performed at 37°C in a mixture of 100 mMHEPES-KOH
(pH 7.5), 30 mM KCl, 12 mMMgCl2, and 2.5 mM DTT, 5 mM ATP, 6.3 nM recombinant
hGatCA (WT, G117E, or G133V), 1.03 μM recombinant hGatB, 65 nM [14C]Glu-tRNAGln and
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2 mM glutamine. Over time, aliquots of the reaction mixture were taken at 0, 1, 5, 10, and
15 min, and were mixed with phenol–chloroform to extract aminoacyl-tRNAs under acidic
conditions, followed by ethanol precipitation and removal of ATP using a Nap5 column. The
amino acids attached to the tRNA were deacylated at 37°C for 30 min in 0.3% aqueous ammo-
nia. The [14C] labeled amino acids were analyzed by thin-layer chromatography (TLC) on a
cellulose plate (Melck) using a basic solvent system (28% ammonia solution:chloroform:meth-
anol, 1:3:4). The TLC plate was exposed to an imaging plate, and the radioactivity was visual-
ized using FLA-7000 image analyzer (Fujifilm).
High-density oligonucleotide array methodology
Samples were processed in accordance with the manufacturer’s instructions. In brief, two ali-
quots of 250 ng genomic DNA were digested with Nsp1 and Sty1, and ligated to adaptors.
Generic primers recognizing the enzyme-specific adaptor sequences were used to amplify
adaptor-ligated DNA. After purification, 270 μg of the PCR product was fragmented and
labeled with biotin. Hybridization was performed in an Affymetrix GeneChip Hybridization
Oven 640, and the arrays were washed and stained in an Affymetrix GeneChip Fluidics Station
450. Arrays were scanned with an Affymetrix GeneChip Scanner 3000 7G. Hardware scripts
were enabled and image processing performed using the Affymetrix GeneChip Command
Console software (AGCC). Genotypes were called using the Affymetrix Genotyping Console
software v4.1.1 GTC with the Birdseed algorithm and a default-calling threshold of 0.1. Sam-
ples were required to have an average minimum Quality Control SNP call rate of 99.7%.
Copy number analysis
All samples were analyzed with GTC v4.1.1. The predicted copy numbers as well as the start
and end of each CNV segment were determined using the Hidden Markov Model. In all data-
sets, hg19 was used. All large CNVs were manually curated. The CNV calls were also generated
using the PennCNV software[68].
Statistics
Results are presented as mean ± SEM or SD for the number of experiments indicated in the fig-
ure legends. Statistical analysis of continuous data was performed with 2-tailed Student’s t test,
as appropriate. p< 0.05 was considered statistically significant.
Study approval
The study was approved by the ethics committee of the Saitama Medical University. Written
informed consent was obtained from all subjects prior to inclusion in this study.
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Supporting Information
S1 Text. Detailed description of identified mutations and variants in this study.
(DOCX)
S1 Fig. Characteristics of 142 unrelated patients with childhood-onset mitochondrial respi-
ratory chain complex deficiencies. Histogram of enzymatic diagnoses in our cohort (A).
Severity was categorized as “Major criteria” or “Minor criteria” on the basis of the level of
enzyme activity reduction (B). Distribution of age at diagnosis (C). Histogram of clinical diag-
noses in our cohort (D). MTDPS, mitochondrial DNA depletion syndrome; ETC, electron
transport chain.
(TIF)
S2 Fig. Flowchart of filtering variants detected by whole exome sequencing.
(TIF)
S3 Fig. Enrichment of prioritized genes in cases in comparison with those in healthy indi-
viduals. One hundred twenty-eight out of 142 cases, and 175 ethnically matched healthy con-
trols whose sequence reads exceeded 50 million were included in the analysis. Percentages of
cases and controls containing prioritized known OXPHOS disease-causing genes were eluci-
dated using simplified exome analysis (A). Percentages of cases and controls containing priori-
tized mitochondria-related genes were elucidated using simplified exome analysis (A).
Percentage of cases and controls containing 908 randomly selected other genes were elucidated
using simplified exome analysis (B).
(TIF)
S4 Fig. Large mtDNA deletion in Pt334. Schematic diagram of mtDNA indicates the deletion
m.11359_15068del3710 (black arc) (A). Gel electrophoresis (1% agarose gel) of a long-range
PCR amplicon shows an 8,701 bp fragment in control DNA and 4,992-bp fragment in Pt334;
All Purpose Lo DNAMarker (BNX) and mtDNA with a deletion from other patient (Single
del) are also included (B). mtDNA sequence coverage (C). Inset shows Sanger electrophero-
gram of the breakpoint.
(TIF)
S5 Fig. BOLA3mutations in Pt045, Pt268, Pt286, and Pt314. Family pedigrees and Sanger
sequencing results for Pt045 (A and B), Pt268 (C andD), Pt286 (E and F), and Pt314 (G and
H). Compound heterozygous mutations c.287A>G (p.H96R) and c.225_229del (p.K75fs) in
BOLA3 (NM_212552) were identified in Pt045. Pt268, Pt286, and Pt314 had a homozygous
mutation c.287A>G (p.H96R) in BOLA3 (NM_212552). Eu means uninformative DNA test.
ClustalW alignment of BOLA3 orthologs. The residue p.H96 is highly conserved (I).
(TIF)
S6 Fig. Complementation assay of Pt045, Pt268, Pt286, and Pt314 fibroblasts. The mito-
chondria were isolated from control or patient fibroblasts following the lentiviral-mediated
expression ofmito-TurboRFP-V5 or BOLA3-V5 cDNA and were analyzed by BN-PAGE/West-
ern blotting and mitochondrial respiratory chain complex enzyme assays. Complementation
with BOLA3-V5 restored the assembly levels of both complexes (A,D,G,J) and enzyme
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activities (C,F,I,L) in all patient fibroblasts. mito-TurboRFP-V5 and BOLA-V5 proteins in the
isolated mitochondria were detected by SDS-PAGE/Western blotting (B,E,H,K). HSP60 was
used as a loading control. RFP,mito-TurboRFP-V5; CS, citrate synthase.
(TIF)
S7 Fig. NDUFAF6mutations in Pt101, Pt330, Pt512, and Pt598. Family pedigrees and elec-
tropherograms for Pt101 (A and B), Pt330 (C andD), Pt512 (E and F), and Pt598 (G andH).
The mutation c.371T>C in NDUFAF6 (NM_152416) was shared between Pt101 and Pt598.
The mutation c.805C>G was found in both Pt101 and Pt512. Eu means uninformative DNA
test.
(TIF)
S8 Fig. Gene structure of NDUFAF6, with gene product protein domains and identified
mutation positions.
(TIF)
S9 Fig. Complementation assay in Pt330 and Pt512 fibroblasts. The mitochondria were iso-
lated from control fibroblasts or Pt330 and Pt512 fibroblasts following the lentiviral-mediated
expression ofmito-TurboRFP-V5, NDUFAF6, or NDUFAF6-V5 cDNA and were analyzed by
BN-PAGE andWestern blotting. Complementation with NDUFAF6 or NDUFAF6-V5 restored
the assembly levels of complex I in patient fibroblasts (A and C). mito-TurboRFP-V5, NDU-
FAF6 and NDUFAF6-V5 proteins in the isolated mitochondria were detected by SDS-PAGE/
Western blotting with anti-V5 and anti-NDUFAF6 antibodies (B andD). HSP60 was used as a
loading control. RFP,mito-TurboRFP-V5. BN-PAGE of mitochondrial fractions from Pt101
and Pt598 fibroblast cells (E and F).
(TIF)
S10 Fig. NDUFB11mutations in Pt067. Family pedigrees of Pt067. The hemizygous
c.391G>Amutation was de novo (A). Electropherograms for Pt067 (B). A hemizygous muta-
tion c.361G>A (p.E121K) inNDUFB11 (NM_001135998) was found in Pt067. Eu means unin-
formative DNA test. ClustalW alignment of NDUFB11 orthologs shows conservation of the p.
E121 residue (C). SDS-PAGE/Western blotting analysis showed a decrease in the endogenous
NDUFB11 protein level in Pt067 fibroblasts. HSP60 was used as a loading control (D). siRNA
knockdown of NDUFB11 in normal fibroblasts. BN-PAGE/Western blotting of mitochondrial
fractions derived from normal human fibroblasts transfected with siNDUFB11 (E). NDUFB11
mRNA and NDUFB11 protein expression in cells treated with siRNAs targeting NDUFB11
(Clone #94, #95 and #96) and control cells (siNega #2) were confirmed by quantitative real-
time PCR and SDS-PAGE/Western blotting, respectively (F and G).
(TIF)
S11 Fig. RNAi-mediated dndufb11 (NP15.6) knockdown in Drosophila melanogaster. Sche-
matic representation of dndufb11 (NP15.6) and dgatA in Drosophila melanogaster (A).
dndufb11 is located in intron 3 of dgatA, a QRSL1 ortholog. Quantitative PCR revealed dramat-
ically reduced dndufb11mRNA levels in RNAi-generated dndufb11-knockdown flies
(arm> dndufb11-IR) to approximately 24% of control levels (arm> GFP-IR), whereas dgatA
mRNA levels were normal (B). All relative values were calculated against data from control
flies. Climbing activities of arm> dndufb11-IR flies and control flies at the age of 6 days (C).
Significance relative to controls was calculated using Student’s t test (; p< 0.01; n.s., not sig-
nificant). The longevity of arm>dndufb11-IRmale flies was dramatically reduced relative to
that of control flies (log-rank test; p< 0.01) (D). Metabolic rate was estimated from CO2 pro-
duction (μl CO2/mg weight/h) of 4-day-old male flies (E). BN-PAGE of mitochondrial fractions
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from arm>dndufb11-IR and control male flies (F). The mitochondria were resuspended in native-
PAGE sample buffer with 1% digitonin. Wedges indicate increasing amounts of mitochondrial
extract (10 μg, 25 μg, 50 μg). Relative amounts of lactate and pyruvate in dndufb11-knockdown
flies against control flies (G). The amounts of metabolites were determined by LC-MS analysis.
Data represent mean ± SEM of at least three experiments. Student's t-test was used to compare the
data between dndufb11-knockdown and control (arm>GFP-IR) flies. (; p< 0.01).
(TIF)
S12 Fig. KARSmutations in Pt459. Family pedigrees of Pt459 (A). Electropherograms for
Pt459 (B). Compound heterozygous mutations c.1343T>A (p.V448D) and c.953T>C (p.
I318T) in KARS (NM_005548) found in Pt459. ClustalW alignment of KARS orthologs shows
conservation of both the p.V448 and p.I318 residues (C). mito-TurboRFP-V5, mtKARS-V5
(mitochondrial isoform of KARS), and cytKARS-V5 (cytosolic isoform of KARS) proteins in
isolated mitochondria were detected by SDS-PAGE/Western blotting with an anti-V5 antibody
(E). HSP60 was used as a loading control. Respiratory chain complex enzyme activity was mea-
sured twice; activity is shown as a percentage of citrate synthase activity. Enzyme activities (D)
and complex I and IV assembly (F) were rescued in Pt459 fibroblasts by the overexpression of
wild-type mitochondrial KARS cDNA. RFP,mito-TurboRFP-V5; mt-KARS, mitochondrial
KARS (NM_001130089)-V5; cyt-KARS, cytosolic KARS (NM_005548)-V5; CS, citrate
synthase.
(TIF)
S13 Fig.MRPS23mutations in Pt276. Electropherograms for Pt276 (A). A homozygous
mutation c.119C>G (p.P40R) inMRPS23 (NM_016070) was found in Pt276. ClustalW align-
ment ofMRPS23 orthologs shows conservation of the p.P40 residue (B). MRPS23-V5 protein
expression inMRPS23-V5-overexpressing Pt276 cell lines was confirmed by SDS-PAGE/West-
ern blotting with an anti-V5 antibody (C). RFP,mito-TurboRFP-V5.
(TIF)
S14 Fig. QRSL1mutations in Pt250 and Pt860. Electropherograms for Pt250 (A) and Pt860
(B). Homozygous and compound heterozygous mutations c.398G>T (p.G133V) and
c.350G>A (p.G117E) in QRSL1 (NM_018292) found in Pt250 and Pt860, respectively.
Sequence alignment of QRSL1 orthologs (C).
(TIF)
S15 Fig.MECP2mutations in Pt053 and Pt369. Family pedigree and electropherograms for
Pt053 (A and B). The c.806delG (p.G269fs) mutation inMECP2 (NM_004992) has been
reported in males with severe neonatal encephalopathy. Family pedigree and electrophero-
grams for Pt369 (C andD). Another novel mutation inMECP2 (NM_001110792) c.17_18insG
(p.A6fs) was identified in Pt369. SDS-PAGE/Western blotting analysis exhibited loss of the
endogenous MECP2 protein level in isolate nuclear fractions from Pt053 and Pt369 fibroblasts
and MECP2 knockdown fibroblasts (E). Lamin A/C was used as a loading control.
(TIF)
S16 Fig. TNNI3mutation in Pt827. Family pedigree for Pt827 (A and B). A heterozygous
mutation c.575G>A (p.R192H) in TNNI3 (NM_000363), which was previously identified in
patients with restrictive cardiomyopathy, was confirmed de novo via Sanger sequencing of the
parents’ DNA. The transmission electron microscope image of the mitochondria in a cardiac
muscle tissue of normal individual and the patient (C). The mitochondria were often enlarged
with increased cristae density. Scale bar, 500 nm.
(TIF)
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S17 Fig. De novo chromosomal microdeletions identified in patients with mitochondrial
respiratory chain deficiency. De novo deletions of 6q24.3-q25.1 were identified using a high-
density oligonucleotide array in Pt452 and Pt695 (A). De novo deletion of 22q11.21 was identi-
fied using a high-density oligonucleotide array in Pt587 (B).
(TIF)
S1 Table. Detailed clinical information. CI, complex I deficiency; CIII, Complex III defi-
ciency; CIV, complex IV deficiency; CC, combined complex deficiencies; CM, cardiomyopathy;
EP, enteropathy; HD, hepatic disease; LD, Leigh's disease; LIMD, lethal infantile mitochondrial
disorder; MC, mitochondrial cytopathy; ND, neurodegenerative disorder; NLIMD, non-lethal
infantile mitochondrial disorder; SS, short stature; SUD, sudden unexpected death; CHD,
congenital heart defect(s); COX, cytochrome c oxidase; CPA, cardiopulmonary arrest; DD,
developmental delay; FTT, failure to thrive; HCM, hypertrophic cardiomyopathy; IUGR, intra-
uterine growth restriction; MOF, multiple organ failure; MRI: magnetic resonance imaging;
RRF, ragged red fiber; SSV, strongly SDH-reactive blood vessel.
(XLSX)
S2 Table. Statistics of sequence reads. CCDS, consensus cDNA (downloaded on 2012.11.14).
(XLSX)
S3 Table. Mutations and pVUS in nuclear DNA.Detailed list of all prioritized variants and all
confirmed pathogenic mutations identified fromWES in this study de_novo, de novomutation
confirmed by trio-based Sanger sequencing; sib_segregate, The variant is segregated with pheno-
types between sibling(s); trio_confirmed_by_Sanger, the variant is confirmed by trio-based Sanger
sequencing; validated_by_cDNA_phasing, phased using cDNA; validated_by_gDNA_phasing,
phased using gDNA; validated_by_sanger, the variant is validated by Sanger sequencing;
chrX_male_mother, the variant is inherited frommother to son not_clear_signal_by_sanger, the
variant is not validated well by Sanger sequencing.
(XLSX)
S4 Table. Mutations and pVUS in mitochondrial DNA. rCRS, revised Cambridge Reference
Sequence (NC_012920); CI, complex I deficiency; CIV, complex IV deficiency; CC, combined
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